Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072141 | 1.00 | NR1H2 (0.42) | NR1H2NR1H3GRM2DRD2OPRM1 | |
| SCHEMBL20074075 | 0.92 | NR1H2 (0.43) | NR1H2NR1H3DRD2OPRM1DRD3 | |
| SCHEMBL20071860 | 0.92 | NR1H2 (0.43) | NR1H2NR1H3DRD2OPRM1DRD3 | |
| SCHEMBL20074047 | 0.91 | NR1H2 (0.49) | NR1H2NR1H3DRD2OPRM1DRD3 | |
| SCHEMBL20071857 | 0.91 | NR1H2 (0.49) | NR1H2NR1H3DRD2OPRM1DRD3 | |
| SCHEMBL23824836 | 0.91 | NR1H2 (0.49) | NR1H2NR1H3DRD2OPRM1DRD3 | |
| SCHEMBL20074076 | 0.91 | NR1H2 (0.49) | NR1H2NR1H3DRD2OPRM1DRD3 | |
| SCHEMBL21686407 | 0.90 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL20072138 | 0.90 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL21644219 | 0.89 | NR1H2 (0.42) | NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885GRM2 604/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | NR1H2 1/4885NR1H3 2/4885GRM2 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.